Akbulut Ekrem
Malatya Turgut Ozal University, Faculty of Engineering and Natural Sciences, Department of Bioengineering, Malatya, Turkey.
Genet Mol Biol. 2022 Apr 29;45(2):e20210404. doi: 10.1590/1678-4685-GMB-2021-0404. eCollection 2022.
3CLpro of SARS-CoV-2 is one of the enzymes required for the replication process of the virus responsible for the COVID-19 pandemic. In this study, changes in protein stability and substrate affinity caused by mutations were investigated to stir the development of potent inhibitors. Sequence data of samples were obtained from the NCBI Virus database. Mutation analyses were performed with RDP4 and MegaX. 3CLpro tertiary models were created using Robetta. Molecular docking for peptidomimetic substrate and inhibitor ligand was done with Autodock v4.2 and Haddock v2.4. Protein stability analysis was performed using mCSM stability and DynaMut2. Twenty-four missense mutations in 3CLpro were identified in this study. Changes in the 3CLpro structure induced by the mutations Met49Thr, Leu167Ser, and Val202Ala resulted in significant levels of instability (-2.029,-2.612,-2.177 kcal.mol-1, respectively). The lowest interaction energy for substrate was -58.7 kcal.mol-1 and -62.6 kcal.mol-1 in wild-type and mutant, respectively. The lowest docking energy for ligand was -6.19 and -9.52 kcal.mol-1 for wild-type and mutant, respectively. This study reports for the first time that mutations cause increased substrate affinity of 3CLpro from SARS-CoV-2. This research provides important data for the development of potent peptidomimetic inhibitors for the treatment of COVID-19.
新型冠状病毒(SARS-CoV-2)的3C样蛋白酶(3CLpro)是引发新冠疫情的病毒复制过程所需的酶之一。在本研究中,对由突变引起的蛋白质稳定性和底物亲和力变化进行了研究,以推动强效抑制剂的开发。样本的序列数据从NCBI病毒数据库获得。使用RDP4和MegaX进行突变分析。使用Robetta创建3CLpro三级模型。使用Autodock v4.2和Haddock v2.4对拟肽底物和抑制剂配体进行分子对接。使用mCSM稳定性和DynaMut2进行蛋白质稳定性分析。本研究在3CLpro中鉴定出24个错义突变。由Met49Thr、Leu167Ser和Val202Ala突变引起的3CLpro结构变化导致显著水平的不稳定性(分别为-2.029、-2.612、-2.177千卡·摩尔-1)。野生型和突变型中底物的最低相互作用能分别为-58.7千卡·摩尔-1和-62.6千卡·摩尔-1。野生型和突变型中配体的最低对接能分别为-6.19千卡·摩尔-1和-9.52千卡·摩尔-1。本研究首次报道突变导致新型冠状病毒3CLpro的底物亲和力增加。该研究为开发用于治疗新冠的强效拟肽抑制剂提供了重要数据。